（文章来源：证券日报） 证券日报网讯泰禾股份11月12日在互动平台回答投资者提问时表示，截至2025年11月10日，公司股东总 户数为12794户。 ...

Group 1 - The core product, Baisijia, is a proprietary product developed by the company, indicating a focus on innovation and product differentiation [2] - The gross margin of the new product, Cyproconazole, is expected to exceed the average gross margin of the company's existing products, suggesting potential for improved profitability [2]

Core Insights - The report highlights the IPO activities in Jiangsu province for October 2025, indicating a stable trend with 9 new A-share companies listed, similar to previous months [1][10]. Group 1: IPO Overview - In October 2025, Jiangsu saw the listing of 1 new company, Changjiang Energy Materials, on the Beijing Stock Exchange, with a fundraising amount of 1.84 billion [2][10]. - For the first ten months of 2025, Jiangsu ranked first among provinces with 21 new A-share companies, surpassing Guangdong by 4 companies [10][17]. - The total fundraising amount for Jiangsu's IPOs in the first ten months reached 129.27 billion, placing it third nationally [17][29]. Group 2: City-wise IPO Distribution - Suzhou led the province with 7 new A-share companies in the first ten months, followed by Wuxi and Changzhou with 3 each [10][17]. - The distribution of new A-share companies by city in October 2025 shows that Jiangsu's cities are actively participating in the IPO market, with various cities contributing to the overall count [5][10]. Group 3: Fundraising Analysis - The total fundraising for Jiangsu's IPOs in October was relatively low at 1.84 billion, indicating a need for more robust fundraising activities [17]. - Suzhou's total fundraising amount for the first ten months was 57.48 billion, maintaining its position as the top city in Jiangsu for IPO fundraising [17][13]. Group 4: Sector and Board Distribution - The newly listed companies in Jiangsu for the first ten months were distributed across four boards, with the Growth Enterprise Market (GEM) having the highest number at 7 companies [17][11]. - The breakdown of the newly listed companies by board shows a diverse participation across different sectors, reflecting the province's economic landscape [11][17]. Group 5: IPO Pipeline and Support - As of the end of October, there were 301 companies in the IPO application queue nationwide, with Jiangsu having 51, ranking third in the country [29]. - Jiangsu also leads in the number of companies undergoing IPO guidance, with 243 firms, indicating a strong support system for potential IPO candidates [29][26].

证券日报网讯泰禾股份（301665）11月11日在互动平台回答投资者提问时表示，江西仰立新材料有限公 司主要从事功能化学品的研发、生产和销售。公司主要产品有间苯二甲胺、二苯甲酮等。间苯二甲胺下 游产品可用于材料类。公司暂不涉及机器人等业务。 ...

Core Viewpoint - The company, Taihe Co., Ltd. (301665), is set to gradually launch its proprietary product, cyhalofop-butyl, globally, with Brazil identified as a key market for expansion. This product is expected to become a new growth driver for the company and facilitate its strategic transition from "generic" to "proprietary," enhancing its global competitiveness [1]. Group 1 - The company will promote the proprietary product cyhalofop-butyl globally [1] - Brazil is a key market for the company's expansion efforts [1] - The product is anticipated to be a new performance growth point for the company [1] Group 2 - The strategic transition from "generic" to "proprietary" is a significant focus for the company [1] - The launch of the new product aims to enhance the company's global competitiveness [1]

格隆汇11月11日丨泰禾股份(301665.SZ)在互动平台表示，江西仰立新材料有限公司主要从事功能化学 品的研发、生产和销售。公司主要产品有间苯二甲胺、二苯甲酮等。间苯二甲胺下游产品可用于材料 类。公司暂不涉及机器人等业务。 ...

Group 1 - The core viewpoint of the article is that Jiangxi Yangli New Materials Co., Ltd. has been recognized as a specialized and innovative company, and there is an inquiry regarding its specific business and product applications [2] - Jiangxi Yangli New Materials Co., Ltd. primarily engages in the research, development, production, and sales of functional chemicals [2] - The main products of the company include m-phenylenediamine and benzophenone, with downstream applications in material-related sectors [2]

Core Insights - The article highlights a trend of decreasing shareholder accounts among 703 companies, with 81 companies experiencing a decline for more than three consecutive periods, indicating a concentration of shares [1][2] Group 1: Shareholder Trends - ST Renzihang has the lowest number of shareholders at 44,499, having decreased for 10 consecutive periods with a cumulative decline of 20.57% [1] - Luoniushan has seen a decrease in shareholder accounts for 9 consecutive periods, with the latest count at 84,500 and a cumulative decline of 12.62% [1] - Other companies with significant declines include Yihua New Materials, Taihe Co., and Yuxin Technology, which have also seen continuous decreases [1] Group 2: Market Performance - Among the companies with declining shareholder accounts, 40 have seen their stock prices rise, while another 40 have experienced declines [2] - Notable stock price increases include Jiaozuo Wanfang at 32.27%, Luoniushan at 25.47%, and ST Xianhe at 19.56% [2] - 23 companies outperformed the Shanghai Composite Index, with Jiaozuo Wanfang, ST Xianhe, and Luoniushan showing relative returns of 27.35%, 16.34%, and 13.31% respectively [2] Group 3: Industry Distribution - The industries with the highest concentration of companies experiencing declining shareholder accounts include machinery, basic chemicals, and automotive, with 10, 9, and 8 companies respectively [2] - The main board has 42 companies with declining shareholder accounts, while the ChiNext board has 39 [2] Group 4: Institutional Interest - In the past month, 10 companies with declining shareholder accounts have been subject to institutional research, with Zhuosheng Micro and Taihe Co. being the most frequently researched, each receiving 2 visits [2] - The companies with the highest number of institutional participants in research include Zhuosheng Micro with 56 institutions, followed by Kairun Co. and Yuxin Technology with 47 each [2]

Group 1: Performance Drivers - The core products 2,4-D, pyraclostrobin, and chlorothalonil have been in high demand, with 2,4-D prices increasing since Q2 and chlorothalonil maintaining stable high prices [2] - In Q3, production facilities operated normally without shutdowns, ensuring capacity release, with a slight increase in 2,4-D output compared to the same period last year [2] - Q3 customer orders were robust, with growth in formulation business in Brazil and other regions, focusing on key product shipments [2] Group 2: Competitive Advantages - The supply of restricted directory products like chlorothalonil and 2,4-D is limited, leading to sustained industry prosperity [2] - The engineering complexity of chlorothalonil production (involving key processes like transamination oxidation and chlorination) has led to the exit of major global players, further constraining supply [3] - 2,4-D has achieved breakthroughs in environmental protection, odor control, and quality management in its production process [3] Group 3: Business Developments - Strategic cooperation has been established with Syngenta domestically, and a global cooperation agreement has been signed with UPL, focusing on independent registration, joint development, and exclusive development [3] - The development of new compounds is aimed at supplementing the product structure, particularly in the fungicide sector, to support stable growth in downstream formulation business [3] - The company is focusing on the fluorinated new materials sector as an extension and upgrade of its functional chemicals segment, leveraging existing technological reserves and industry experience [3] Group 4: Incentive Planning - The company is formulating a multi-tiered talent incentive plan to attract industry talent, aligned with global expansion, innovative business, and multi-industry chain development needs; the plan is currently in the adjustment phase with no clear timeline for implementation [3] Group 5: Risk Warning - The information discussed in this research does not constitute a substantive commitment to investors regarding external environment assessments, company development strategies, or future plans; investors are advised to invest rationally and be aware of investment risks [3]

Core Viewpoint - The continuous decline in the number of shareholders for many companies indicates a trend of increasing concentration of shares, with 841 companies reporting their latest shareholder numbers as of October 20, and 127 companies experiencing a decline for more than three consecutive periods [1][2]. Shareholder Trends - A total of 841 companies disclosed their latest shareholder counts, with 127 companies showing a decline for over three periods, and some, like *ST Zhongdi, experiencing a drop for 16 consecutive periods, with a cumulative decrease of 26.41% [1]. - Notable companies with significant declines include *ST Zhongdi (29,865 shareholders, down 26.41%) and Fengshang Culture (13,463 shareholders, down 44.86%) [1][2]. Market Performance - Among the companies with declining shareholder numbers, 38 saw their stock prices rise, while 86 experienced declines. Companies like Jingquanhua, Changshan Pharmaceutical, and China Merchants Energy had notable increases of 54.53%, 47.70%, and 43.87%, respectively [2]. - 19 companies outperformed the Shanghai Composite Index, with Jingquanhua, Changshan Pharmaceutical, and China Merchants Energy achieving relative returns of 51.00%, 44.18%, and 41.36% [2]. Institutional Interest - In the past month, 18 companies with declining shareholder numbers were subject to institutional research, with Feilong Co., Boshijie, and Minbao Guangdian receiving the most attention, having been researched 4, 2, and 2 times, respectively [2]. - The companies with the highest number of institutional participants include Meihua Medical (72 institutions), Jingbeifang (56 institutions), and Zhuoshengwei (56 institutions) [2]. Financial Performance - 125 companies have released their Q3 reports, with *ST Zhongdi showing the highest year-on-year net profit growth of 424.13% [3].